Prostate Cancer News
Urine-derived extracellular vesicle RNA provides diagnostic, prognostic information in prostate cancer.
Men on active surveillance for prostate cancer progress to treatment sooner if they undergo multiparametric MRI to identify clinically significant tumors.
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Radical prostatectomy and ablation for salvage treatment of radiorecurrent prostate cancer do not differ significant with regard to cancer-specific and metastasis-free survival, a study found.
A lesion visible on magnetic resonance imaging (MRI) identifies a heightened risk for clinically significant prostate cancer in men undergoing first-time prostate biopsy, and a combination of targeted and systematic biopsy may improve the chances of detecting cancer.
Older men with favorable intermediate-risk prostate cancer treated in the West, Northwest, or Midwest were the biggest adopters of AS during the years 2010 and 2015.
Abiraterone plus prednisone combined with leuprolide decreases tumor size compared with leuprolide alone in men with high-risk prostate cancer.
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
Specific fat deposits, body mass index (BMI), and waist circumference are associated with an increased risk for advanced and fatal prostate cancer.
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Approximately 45% of men with newly diagnosed, hormone-sensitive prostate cancer enrolled in the ENZAMET trial also received early treatment with docetaxel.
Long-term follow-up of the randomized GETUG-AFU 16 study confirmed a significant improvement in metastatic-free survival when goserelin was added to salvage RT.
Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
In 2015, black men were 16% less likely than nonblack men to choose active surveillance or watchful waiting for low-risk prostate cancer.
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
New data from a phase 2 randomized trial suggest that stereotactic ablative radiotherapy to sites of metastases may prolong overall and progression-free survival.